We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+41.17%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$1.01B
AUM Growth
+$219M
Cap. Flow
+$20.1M
Cap. Flow %
1.99%
Top 10 Hldgs %
55.14%
Holding
55
New
15
Increased
6
Reduced
11
Closed
15

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$36.3M
2
GNFT
Genfit
GNFT
+$28.4M
3
EPZM
Epizyme, Inc
EPZM
+$24.3M
4
PTCT icon
PTC Therapeutics
PTCT
+$19.8M
5
CTMX icon
CytomX Therapeutics
CTMX
+$14.2M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$24.7M
2
CYTK icon
Cytokinetics
CYTK
+$20.1M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$17.6M
4
PBYI icon
Puma Biotechnology
PBYI
+$14.7M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
1
PTC Therapeutics
PTCT
$5.64B
$68.3M 6.76%
1,814,260
+589,260
+48% +$19.8M
ZGNX
2
DELISTED
Zogenix, Inc.
ZGNX
$66M 6.53%
1,199,545
+199,545
+20% +$9.49M
GBT
3
DELISTED
Global Blood Therapeutics, Inc.
GBT
$62.5M 6.18%
1,180,000
– –
BOLD
4
DELISTED
Audentes Therapeutics, Inc
BOLD
$61.4M 6.07%
1,572,618
-85,255
-5% -$2.44M
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.43B
$53.7M 5.32%
2,000,000
-752,256
-27% -$17.6M
IOVA icon
6
Iovance Biotherapeutics
IOVA
$1.82B
$52.9M 5.24%
5,567,348
– –
XLRN
7
DELISTED
Acceleron Pharma
XLRN
$50.3M 4.98%
1,080,113
+43,538
+4% +$1.91M
ASND icon
8
Ascendis Pharma A/S
ASND
$16B
$48.8M 4.83%
+415,000
New +$36.3M
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.28B
$48.5M 4.8%
5,955,762
-1,666,494
-22% -$14.3M
ICPT
10
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$44.7M 4.43%
400,000
+200,000
+100% +$21.9M
UTHR icon
11
United Therapeutics
UTHR
$25.8B
$44.6M 4.41%
379,832
+29,032
+8% +$3.38M
ARRY
12
DELISTED
Array Biopharma Inc
ARRY
$43.9M 4.34%
1,800,000
-50,000
-3% -$1.04M
KURA icon
13
Kura Oncology
KURA
$800M
$43.9M 4.34%
2,645,100
-124,427
-4% -$1.92M
PBYI icon
14
Puma Biotechnology
PBYI
$404M
$34.9M 3.46%
900,000
-479,700
-35% -$14.7M
FPRX
15
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$32.1M 3.18%
2,398,409
– –
GNFT
16
DELISTED
Genfit
GNFT
$29.5M 2.92%
+1,230,314
New +$28.4M
EPZM
17
DELISTED
Epizyme, Inc
EPZM
$26.9M 2.67%
+2,173,913
New +$24.3M
ASND icon
18
PUT
Ascendis Pharma A/S
ASND
$16B
$23.5M 2.33%
+200,000
New +$17.5M
DERM
19
DELISTED
Dermira, Inc.
DERM
$20.3M 2.01%
+1,500,000
New +$12.5M
TPST icon
20
Tempest Therapeutics
TPST
$13.7M
$19.3M 1.91%
6,606
– –
KRYS icon
21
Krystal Biotech
KRYS
$10.1B
$16.2M 1.6%
492,100
– –
YARW
22
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$16.1M 1.6%
571
-41
-7% -$984K
CBAY
23
DELISTED
Cymabay Therapeutics
CBAY
$13.3M 1.31%
998,841
-419,648
-30% -$4.46M
KYNB
24
PUT
Kyntra Bio
KYNB
$27.2M
$10.9M 1.08%
+8,000
New +$10.8M
CTMX icon
25
CytomX Therapeutics
CTMX
$675M
$10.3M 1.02%
+959,077
New +$14.2M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2019 Portfolio in Review

As of Q1 2019, Great Point Partners held 55 positions worth $1.01B, up 28% from $791M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Great Point Partners's Q1 2019 filing shows 15 new, 6 increased, 11 reduced and 15 closed positions. Its largest new stake was Ascendis Pharma A/S: 415,000 shares worth $48.8M. The largest sale was Spark Therapeutics, Inc. Common Stock, an estimated $24.7M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier.

  • Great Point Partners's largest Q1 2019 buy was Ascendis Pharma A/S: 415,000 shares worth $48.8M.
  • Great Point Partners added most to PTC Therapeutics in Q1 2019, an estimated $19.8M increase.
  • Great Point Partners's biggest Q1 2019 reduction was Acadia Pharmaceuticals, cutting an estimated $17.6M.
  • Great Point Partners fully exited Spark Therapeutics, Inc. Common Stock in Q1 2019, selling an estimated $24.7M.
  • Great Point Partners's ten largest holdings make up 55% of its $1.01B portfolio in Q1 2019.
  • Great Point Partners opened 15 new positions and closed 15 in Q1 2019.
  • Great Point Partners's portfolio value rose 28% quarter-over-quarter to $1.01B.

Based on Great Point Partners's 13F filing for Q1 2019, filed 14 May 2019.